Determination of Drug Interactions of Certain Nasal Medications With Intranasal Ketamine

Phase 1UnknownNCT00520104

Javelin Pharmaceuticals48 enrolled

Overview

This is an open label, single-center study to determine whether certain nasal medication interact with PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers and in patients with allergic rhinitis.

To assess separately the effects of a nasal vasoconstrictor (oxymetazoline) and of a nasal steroid on the rate and extent of intranasal absorption of PMI-150 30 mg.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Pharmacokinetics

Interventions

intranasal ketamineDRUG

drug interaction

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy adults * Patients with Allergic Rhinitis Exclusion Criteria: * Under age 18

Locations (1)

Javelin Pharmaceuticals

Cambridge, Massachusetts, United States

Outcomes

Primary Outcomes

Pharmacokinetics

Time frame: multiple

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.